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Abstract
Background: Hydroxyzine is indicated for the management of anxiety, skin and sleep
disorders. In 2015, the European Medicines Agency (EMA) concluded that hydroxy-
zine was pro-arrhythmogenic and changes to the product information were
implemented in Europe. This study aimed to evaluate their impact in Denmark, Scot-
land, England and the Netherlands.
Method: Quarterly time series analyses measuring hydroxyzine initiation, discontinu-
ation, and switching to other antihistamines, benzodiazepines and antidepressants in
Denmark, England, Scotland and the Netherlands from 2009 to 2018. Data were
analysed using interrupted time series regression.
Results: Hydroxyzine initiation in quarter one 2010 in Denmark, Scotland, England
and the Netherlands per 100 000 was: 23.5, 91.5, 35.9 and 34.4 respectively. Regu-
latory action was associated with a significant: immediate fall in hydroxyzine initia-
tion per 100 000 in England (−12.05, 95%CI −18.47 to −5.63) and Scotland
(−19.01, 95%CI −26.99 to −11.02); change to a negative trend in hydroxyzine initi-
ation per 100 000/quarter in England (−1.72, 95%CI −2.69 to −0.75) and Scotland
(−2.38, 95%CI −3.32 to −1.44). Regulatory action was associated with a significant:
immediate rise in hydroxyzine discontinuation per 100 000 in England (3850, 95%
CI 440-7240). No consistent changes were observed in the Netherlands or
Denmark. Regulatory action was associated with no switching to other antihista-
mines, benzodiazepines or antidepressants following hydroxyzine discontinuation
in any country.
Conclusion: The 2015 EMA regulatory action was associated with heterogeneous
impact with reductions in hydroxyzine initiation varying by country. There was limited
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impact on discontinuation with no strong evidence suggesting unintended conse-
quences of major switching to other antihistamines, benzodiazepines or antidepressants.
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1 | INTRODUCTION
Hydroxyzine is an antihistamine approved in Europe for the manage-
ment of anxiety, skin and sleep disorders. In February 2015,
the European Medicines Agency (EMA) examined the pro-
arrhythmogenic potential of hydroxyzine based on evidence from
clinical and post-marketing safety data.1 The EMA safety review
concluded that although hydroxyzine containing medicinal products
are effective treatments for their approved indications, in order for
the benefit–risk balance of hydroxyzine to remain favourable, con-
traindications, warnings, and changes to the product information,
including a direct healthcare professional communication (DHPC)
were required to be implemented across the European Union (EU).
Hydroxyzine was contraindicated in people with cardiovascular dis-
ease (CVD) and in those prescribed medicines known to prolong the
QT interval.1
When new safety information emerges about a medicine, effec-
tive communication is essential to minimise harm. The benefit–risk
profile of medicines is constantly evaluated by the EMA, which is
responsible for cascading new safety information through the
European pharmacovigilance network to alert prescribers and
patients. However, the impact of such regulatory actions on
healthcare professional behaviour is often poorly understood despite
their enormous potential to affect public health.2,3 One of the EMAs
responsibilities now includes measuring the effectiveness of their reg-
ulatory actions, which led the EMA to commission a study on
hydroxyzine to support the EMA Pharmacovigilance Risk Assessment
Committee (PRAC) decision making. The aim of this study was there-
fore to evaluate the impact of the EMA risk minimisation measures
implemented in 2015 following the EMA PRAC referral procedure for
hydroxyzine using data from Denmark, England, Scotland, and the
Netherlands.
2 | METHODS
2.1 | Data sources
Four data sources were analysed (please see Supporting Information
Methods for further details). In brief these were:
• The Clinical Practice Research Datalink (CPRD), which contains pri-
mary care data. For this analysis only up-to-standard data from
English practices within the UK was used.4
• The Scottish Prescribing Information System (PIS), which records
all dispensed medicines from pharmacies in Scotland (UK) that can
be record-linked to demographic data, hospital admissions and
attendances, and death registrations nationally within Scotland.5
• The Danish Register of Medicinal Products, which records all out-
of-hospital prescriptions and allows linkage of drug exposures to
inpatient and outpatient hospital contacts in the Danish National
Patient Registry, including death data from the Civil Registration
System.6-8
• The Dutch PHARMO Database Network, which combines data
from primary and secondary care in the Netherlands. These differ-
ent data sources, including data from general practices, in- and
out-patient pharmacies, clinical laboratories, hospitals, the cancer
registry, pathology registry and perinatal registry, and which are
linked on a patient level through validated algorithms.9
2.2 | Study population
Cohorts were generated to provide time series data for analysis using
a common protocol (EU PAS Register number EUPAS24089).10 The
start period varied by the availability of data from each database.
Cohort entry was defined as the latest of the following: study start
date; date of registration with the general practice (in CPRD and
PHARMO); availability of data collection; having at least 1 year of
observation (lookback period). For cohorts associated with the target
condition (a new contraindication), cohort entry was additionally
defined by the date when the condition was first recorded. Con-
traindicated patients included those patients with: (a) a known risk
factor to QT interval prolongation consisting of CVD disease and;
KEY POINTS
• Hydroxyzine initiation fell following the 2015 EMA regu-
latory action
• EMA regulatory action had a variable effect on hydroxy-
zine initiation
• EMA regulatory action was associated with no major
switching to other antihistamines, benzodiazepines or
antidepressants
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(b) concomitant use of medicines known to prolong the QT interval
and/or induce Torsades de Pointes (please see Supporting Information
Methods for further details).
A patient's index date was the latest of the study period start date,
the date of birth, or their first database follow up date plus 1 year
(to allow sufficient time to determine prevalent versus incident use of
medicines). A patient's last follow up date was the first occurrence of
the following: death (all databases); end of study period (varies between
countries); end of registration within the data source (end of registration
would not significantly affect data from Denmark and Scotland because
they use national data that captures patients moving within the health
system). A patient was included in the time period aggregate if the first
and last day both lay between the patient's index date and their last fol-
low up date, so patients were observable for the entire quarter.
2.3 | Exposure
The exposure was the conclusion of the 2015 EMA PRAC referral
procedure when recommendations aimed at reducing the risk of heart
rhythm disturbances associated with use of hydroxyzine first became
public (Box 1).1
2.4 | Outcomes
The outcomes of interest evaluated whether there was any immediate
change in prescribing at the time of the regulatory action (pre-
specified as February 2015) and/or change in prescribing trend post-
intervention compared to the baseline trend. These were analysed as
a series of proportions from aggregated patient counts evaluated in
each quarter over the study period.
• Hydroxyzine prescribing initiation overall
• Hydroxyzine prescribing initiation by recorded history of an indica-
tion, age, gender, and exposure type
• Hydroxyzine prescribing discontinuation overall
• Switching patterns to alternative medicines following hydroxyzine
discontinuation
Hydroxyzine initiation was defined as a prescription for hydroxy-
zine with no exposure to hydroxyzine in the preceding 92 days. The
denominator was the number of non-users on the first day of the time
period defined as no exposure to hydroxyzine in the previous 92 days.
Exposure type was defined as one-off use, sporadic use or chronic use.
One-off users were defined as patients prescribed a single hydroxyzine
prescription only. To define sporadic and chronic users we calculated a
possession ratio for each patient defined by using the number of days
prescribed (or supplied) assuming a standard daily dose divided by the
number of days between hydroxyzine prescriptions. We defined spo-
radic users as patients with a hydroxyzine possession ratio of less than
1 standard day of therapy per 3 days. Patients with a hydroxyzine pos-
session ratio of more than 1 standard day of therapy per 3 days were
defined as chronic users. Hydroxyzine discontinuation was defined as
the number of patients with a prescription for hydroxyzine with no fur-
ther exposure to hydroxyzine in the 92 days following the date of pre-
scription. The denominator was the number of patients prescribed
hydroxyzine in the time period. The numerator was the number of
patients discontinuing. For patients with contraindications to hydroxy-
zine, only hydroxyzine initiation was examined. A switch to an alterna-
tive medicine class was defined as those patients who discontinued
hydroxyzine and who then initiated a drug in the class listed in
Table S6. Initiation of an alternative medicine was defined as the first
prescription of a drug in that class prescribed within 92 days following
the date of the last hydroxyzine prescription. Please see online
Supporting information methods section for further details.
2.5 | Statistical analysis
The study design was an interrupted time series regression analysis of
prescribing trends. The primary analysis used interrupted time series
regression to fit quarterly time trends for each country. The effect of
the intervention for each country was represented either by a step
function, or by a continuous linear function modelling the baseline
slope before the intervention time point, the change in slope from the
baseline time periods to the post-intervention time periods and the
immediate change associated with the intervention time point as
described by Wagner et al.11 Interrupted time series regression was
done for hydroxyzine initiation rates, hydroxyzine discontinuation
rates, and for patients switching to the alternative classes of medi-
cines stratified by country. Time points with cell counts fewer than
five were suppressed. Before fitting all regression models, the data
was visualised graphically. Trends were modelled using weighted lin-
ear regression, the weights being the denominators in each propor-
tion. All models were checked for autocorrelation using the Durbin-
Box 1 Summary of EMA recommended measures
to minimise the risk of heart rhythm problems with
hydroxyzine use
• Use must be avoided in patients who already have risk
factors for heart rhythm disturbances orare taking other
medicines that increase the risk of QT prolongation.
• Use is not recommended in the elderly.
• Use hydroxyzine at the lowest effective dose for as short
a time a s possible.
• The maximum daily dose of hydroxyzine should be no
more than 100 mg in adults (50 mg in theelderly if use
cannot be avoided), and 2 mg per kg body weight where
used in children up to 40kg in weight.
• Care is needed in patients taking medicines that slow the
heart rate or decrease the level of potassium in the
blood, as these also increase the risk of problems with
heart rhythm.
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Watson statistic. All analyses were carried out using SAS Version 9.4
Copyright 2002–2012 SAS Institute Inc., Cary, North Carolina.
2.6 | Ethical permissions
Permission to conduct the study in each database was obtained from
the relevant source from each country, according to each databases'
standard terms and conditions.
3 | RESULTS
Over the study period the population consisted of approximately: 5.6
million from Denmark; 5.3 million from Scotland; 4.2 million from
England; and 1 million from the Netherlands. The prevalence of
hydroxyzine initiation at baseline per 100 000 patients was 23.5 in
Denmark, 91.5 in Scotland, 35.9 in England and 34.4 in the Nether-
lands (Table 1). Over the study period the prevalence of hydroxyzine
initiation fell, apart from in Denmark. The most common recorded
TABLE 1 Prevalence of hydroxyzine initiation at the beginning and end of overlapping follow-up periods for each country









(per 100 000) Relative (%)
Denmark 2010Q1 23.5 2018Q1 24.6 1.1 (−1.4 to 3.3) 4.7 (−6.0 to 14.0)
England 2009Q1 35.9 2018Q1 30.8 −5.1 (−10.3 to 0.3) −14.2 (−28.7 to 0.8)
The Netherlands 2009Q2 34.4 2017Q4 25.4 −9 (−20.7 to 1.9) −26.2 (−60.2 to 5.5)
Scotland 2009Q1 91.5 2018Q2 58.9 −32.6 (−38.2 to −27.1) −35.6 (−41.7 to −29.6)
F IGURE 1 Trends in overall hydroxyzine initiation in Denmark, England, the Netherlands and Scotland [Colour figure can be viewed at
wileyonlinelibrary.com]
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TABLE 2 Interrupted time series regression results for trends in hydroxyzine initiation and discontinuation in each country
Country
Trend (95% CI) in hydroxyzine
initiation before February 2015
(per 100 000/quarter)
Change (95% CI) in hydroxyzine
initiation in first quarter after
February 2015 (per 100 000)
Change in trend (95% CI) in
hydroxyzine initiation after February
2015 (per 100 000/quarter)
Initiation
Denmark 0.27 (0.10 to 0.44) −1.66 (−4.93 to 1.61) −0.22 (−0.61 to 0.16)
England 0.68 (0.46 to 0.89) −12.05 (−18.47 to −5.63) −1.72 (−2.69 to −0.75)
The Netherlands −0.10 (−0.40 to 0.20) −5.08 (−10.92 to 0.77) 0.16 (−0.70 to 1.03)
Scotland 0.58 (0.21 to 0.96) −19.01 (−26.99 to −11.02) −2.38 (−3.32 to −1.44)
Discontinuation
Denmark 346 (211 to 481) −2905 (−5328 to −481) −425 (−710 to −139)
England −246 (−375 to −116) 3852 (439 to 7264) −558 (−109 to −23)
The Netherlands −409 (−710 to −108) 2560 (−3660 to 8781) −512 (−1435 to 412)
Scotland −263 (−414 to −112) 794 (−2082 to 3671) −181 (−529 to 167)
Note: The denominator for hydroxyzine initiation was the number of non-users on the first day of the time period defined as no exposure to hydroxyzine
in the previous 92 days. The denominator for hydroxyzine discontinuation was the number of patients prescribed hydroxyzine in the time period.
F IGURE 2 Trends in overall hydroxyzine discontinuation in Denmark, England, the Netherlands and Scotland [Colour figure can be viewed at
wileyonlinelibrary.com]
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history of an indication in people initiating hydroxyzine in all countries
was skin disorder.
3.1 | Impact of the regulatory action on
hydroxyzine initiation
Trends in overall hydroxyzine initiation in each country are shown in
Figure 1 and in Table 2. In Denmark, England and Scotland there
was a positive trend in hydroxyzine initiation at baseline, whilst in
the Netherlands there was no trend. In England and Scotland the
regulatory action was associated with an immediate fall in hydroxy-
zine initiation (−12.05, 95%CI −18.47 to −5.63 per 100 000 and
−19.01, 95%CI −26.99 to −11.02 per 100 000 respectively). No
immediate change was observed in Denmark or the Netherlands
(Table 2). Post-intervention, the regulatory action was associated
with a change to a negative trend in hydroxyzine initiation in
England and Scotland (−1.72, 95%CI −2.69 to −0.75 per 100 000/
quarter and −2.38, 95%CI −3.32 to −1.44 per 100 000/quarter
respectively). No change in trend was observed in Denmark or the
Netherlands.
3.2 | Trends in hydroxyzine initiation stratified by
age, gender and exposure type
Trends in hydroxyzine initiation by age, gender and exposure type are
shown in Figures S1 to S4 and Tables S1 to S4. Hydroxyzine initiation
was greater in women than men and consisted mainly of one-off use.
The regulatory intervention was associated with immediate reduc-
tions: in all exposure types in England; one-off and sporadic exposure
in Scotland; sporadic exposure in the Netherlands. Post-intervention,
there was a change to a negative trend in all exposure types in
England and one-off and chronic exposure in Scotland.
Hydroxyzine initiation increased with age. In general, trends for
hydroxyzine initiation by age in England and Scotland followed overall
trends (Tables S2 and S3). In Denmark, a negative trend in hydroxy-
zine initiation was observed in people aged 18–29 and 30–39 years
F IGURE 3 Trends in switching from hydroxyzine to other antihistamines in Denmark, England, the Netherlands and Scotland [Colour figure
can be viewed at wileyonlinelibrary.com]
6 MORALES ET AL.
with an immediate fall in those aged 60–69 years (Table S3). In the
Netherlands an immediate fall was observed in people aged 18–29
and 60–69 years (Table S4).
3.3 | Impact of the regulatory action on
hydroxyzine discontinuation
The results for hydroxyzine discontinuation are shown in Figure 2
and in Table 2. The baseline trend in hydroxyzine discontinuation
was negative in all countries apart from in Denmark, where there
was a positive trend. In Denmark, the regulatory action was associ-
ated with an immediate fall in hydroxyzine discontinuation
(−2905, 95%CI −5328 to −481 per 100 000) and a change to a
negative trend (−425, 95%CI −710 to −139 per quarter) post-
intervention. In England, the regulatory action was associated with
an immediate rise in hydroxyzine discontinuation (3852, 95%CI
439-7264) and a change to a negative trend in discontinuation
(−558, 95%CI −109 to −23). No changes were observed for Scot-
land and the Netherlands.
TABLE 3 Interrupted time series regression results for trends in switching to alternative medicines
Country
Trend (95% CI) in switching to
alternative medicines before
February 2015 (per 100 000/quarter)
Change (95% CI) in switching to
alternative medicines in first quarter
after February 2015 (per 100 000)
Change in trend (95% CI) in switching
to alternative medicines after
February 2015 (per 100 000/quarter)
Denmark
Other antihistamines −92 (−193 to 9) 1058 (−706 to 2823) 24 (−161 to 208)
Benzodiazepines −76 (−144 to −9) 263 (−906 to 1431) −13 (−135 to 110)
Other medications 66 (−9 to 141) −471 (−1775 to 832) −101 (−237 to 36)
England
Other antihistamines −27 (−92 to 38) 1237 (−587 to 3061) −187 (−486 to 112)
Benzodiazepines 7 (−14 to 27) 184 (−423 to 791) −50 (−175 to 76)
Other medications 1 (−34 to 36) 172 (−818 to 1162) −17 (−179 to 145)
The Netherlands
Other antihistamines −200 (−308 to −92) 1216 (−1084 to 3516) 165 (−232 to 562)
Benzodiazepines −73 (−112 to −33) 481 (−493 to 1456) 31 (−1232 to 1293)
Other medications 122 (−1539 to 1783) 372 (−2350 to 2424) −355 (−3503 to 2792)
Scotland
Other antihistamines −63 (−158 to 31) 1092 (−790 to 2975) −65 (−300 to 171)
Benzodiazepines −24 (−40 to −8) 315 (−6 to 635) 31 (−10 to 71)
Other medications −27 (−67 to 14) −99 (−909 to 711) 95 (−6 to 196)
Note: The denominator for switching was the number of patients discontinuing hydroxyzine in the time period. Other medications = tricyclic
antidepressants, mirtazapine and SSRIs.




Trend (95% CI) in hydroxyzine
initiation before February 2015 (per
100 000/quarter)
Change (95% CI) in hydroxyzine
initiation in first quarter after
February 2015 (per 100 000)
Change in hydroxyzine initiation in
trend (95% CI) after February 2015
(per 100 000/quarter)
Cardiovascular disease
Denmark 0.13 (−0.46 to 0.72) −7.22 (−18.11 to 3.67) −0.02 (−1.31 to 1.26)
England 2.06 (1.30 to 2.82) −36.47 (−59.42 to −13.51) −3.20 (−6.75 to 0.36)
The Netherlands −1.48 (−2.61 to −0.35) −5.73 (−22.81 to 11.35) 1.14 (−1.26 to 3.55)
Scotland 1.27 (0.25 to 2.29) −46.16 (−69.98 to −22.34) −3.79 (−6.60 to −0.98)
QT prolonging medicinesa
Denmark 1.74 (1.02 to 2.45) −7.03 (−20.97 to 6.92) −1.69 (−3.36 to −0.022)
England 2.26 (1.45 to 3.07) −57.06 (−84.69 to −29.44) −8.51 (−16.24 to −0.77)
The Netherlands −1.68 (−2.86 to −0.50) −7.89 (−31.14 to 15.37) 2.05 (−1.36 to 5.45)
Scotland 1.90 (0.95 to 2.85) −50.10 (−71.07 to −29.12) −7.45 (−9.92, −4.98)
aAnd/or medicines known to induce Torsades de Pointe. The denominator for hydroxyzine initiation was the number of non-users on the first day of the
time period defined as no exposure to hydroxyzine in the previous 92 days for each target cohort.
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3.4 | Impact of the regulatory action on switching
to other antihistamines, benzodiazepines or
antidepressants
Trends in switching to alternative medicines are shown in Figure 3,
Figures S5 and S6 and in Table 3. The regulatory action was associ-
ated with no immediate change in switching to other antihistamines,
benzodiazepines or antidepressant and no significant change in trend
post-intervention in any country.
3.5 | Impact of the regulatory action on
hydroxyzine initiation in patients with
contraindications
Trends in hydroxyzine initiation by contraindication are shown in
Table 4 and Figures S7 and S8. The baseline trend in hydroxyzine initi-
ation in patients with CVD was positive in England and Scotland, neg-
ative in the Netherlands. The regulatory action was associated with an
immediate fall in hydroxyzine initiation in patients with CVD in Scot-
land and England and a change to a negative trend in Scotland post-
intervention.
The baseline trend in hydroxyzine initiation in patients prescribed
medicines known to prolong the QT interval and/or induce Torsades
de Pointes was positive in all countries apart from the Netherlands,
which had a negative trend. The regulatory action was associated with
an immediate fall in hydroxyzine initiation in these patients in Scot-
land and England and a change to a negative trend in Scotland,
England and Denmark post-intervention.
4 | DISCUSSION
Over the study period, the prevalence of hydroxyzine initiation fell by
36, 26 and 14% in Scotland, England and the Netherlands respectively
but not in Denmark. The EMA regulatory action for hydroxyzine was
associated with immediate falls in hydroxyzine initiation in England
and Scotland by 12 and 19 per 100 000 respectively, which represen-
ted a 20% immediate fall compared to the preceding quarter. In
Denmark and the Netherlands impact was more limited, with evidence
suggesting it may have occurred only in certain age groups, and for
Denmark, in those prescribed medicines known to affect the QT inter-
val. The regulatory action was associated with an immediate 15% rise
in hydroxyzine discontinuation in England compared to the previous
quarter. However, no impact on hydroxyzine discontinuation was
observed in the Netherlands or Scotland, whilst a fall was observed in
Denmark. The regulatory action was not associated with a major
impact on switching to other antihistamines, benzodiazepines or
antidepressants.
The use of hydroxyzine in each country was low suggesting it
was not the clinically preferred antihistamine. For example, although
Scotland had the highest prevalence of hydroxyzine initiation, being
approximately fourfold higher compared to the Netherlands and
Denmark, in 2016 it represented only 4.9% of all antihistamine pre-
scribing in Scotland.12
For regulatory actions to be effective, knowledge should be effec-
tively disseminated, communicated and understood, and how this
occurs may affect the size of any impact.13 If prescribing levels are
already very low, it is possible that regulatory actions may struggle to
demonstrate significant impact unless particularly focused on a nar-
row target population. This is because healthcare professionals may
perceive them as being less important and may not be widely dis-
cussed among educational resources or incorporated into guidelines.
In this regard, it is possible that use may already be limited to those
patients who have a real need for the medicine (i.e., that it has
established effectiveness so that they are less likely to discontinue
treatment). Despite levels of prescribing being low in all countries,
variation in impact was still observed. Therefore perceived lack of
importance or established effective use among people who need
treatment are perhaps less likely explanations.
Heterogeneity in impact can be associated with the type of warn-
ing and method of dissemination. For example, DHPCs have been
associated with an average change in targeted prescribing of 47%
compared to 13% communicated via drug bulletins.14 In this regard, a
2004 UK risk communication relating to antipsychotic use in dementia
disseminated via DHPC led to greater changes in prescribing in Scot-
land compared to a 2009 less-specific communication detailed in a
drug bulletin. Differences were observed between Scotland and
England.15,16 Furthermore, heterogeneity may result from differences
in the timing of implementation within each country. For example the
DHPCs appear to have been disseminated on 21 April, 27 April and
4 May in the Netherlands, UK and Denmark respectively.17-19 How-
ever, other downstream factors may also have influenced this process
and therefore we used the quarter when the referral concluded as our
intervention time point when information first became public. Never-
theless, we add to the evidence demonstrating geographical variation
in the impact of pharmacovigilance decisions can occur despite being
subject to the same recommendations.3,20-25
Regulatory interventions may be associated with unintended con-
sequences such as substitute prescribing or switching that may them-
selves lead to adverse effects.20,26 Evaluating such effects, is often
subject to methodological limitations.2,3 Specific to hydroxyzine, it
would be of concern if patients switched to benzodiazepines that are
associated with an increased risk of addiction and mortality to manage
anxiety.27 Similarly, switching to an antihistamine with more sedative
properties may also have unintended effects such as increasing road
traffic accidents.28 Reassuringly, we observed there is no strong evi-
dence suggesting the regulatory action for hydroxyzine caused wide-
spread substitute prescribing for those medicines that we evaluated.
We noted that the regulatory action seemed to have less impact
on hydroxyzine discontinuation compared to initiation. This would be
in keeping with the findings from a systematic review examining the
impact of United States risk advisories, which suggested such
advisories were more effective at decreasing initiation of targeted
medicines and less effective at bringing about their discontinuation.2
This has also been seen with another recent European study.20 While
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the immediate rise in hydroxyzine discontinuation in England is con-
sidered an intended effect, it is uncertain why hydroxyzine discontinu-
ation should have fallen in Denmark particularly when the rate of
hydroxyzine initiation did not change. However, the post-intervention
negative trend in discontinuation in England may be because the pool
of hydroxyzine initiators was falling, an effect seen elsewhere.20
4.1 | Strengths and limitations
To our knowledge, this study is the largest study examining
hydroxyzine prescribing in Europe, the findings of which may sup-
port the EMA strategy for examining the impact of
pharmacovigilance decisions. It uses high quality data sources and a
common protocol and data extraction method to standardise data
from each country. However, the study has several potential limita-
tions. Firstly, our data sources do not capture over the counter
antihistamine use that may underestimate the prevalence of
switching to other antihistamines. Furthermore, indications were
determined by coded diagnoses that are more commonly recorded
in primary care than hospital data sources. For this reason the pro-
portion of patients with an indication was greater for England and
the Netherland compared to Denmark and Scotland, which report
trends for patients with indications attending secondary care. Sec-
ondly, due to the lower prevalence of hydroxyzine exposure, many
subgroup analyses meant that cell counts less than five were
detected that affected precision and their ability to be reported.
Thirdly, although ITS analysis is a robust quasi-experimental design
commonly used to evaluate policy interventions, it only examines
associations that may be confounded by other interventions occur-
ring simultaneously.29 Data presented in this manuscript are
population-average estimates. Therefore variation may still exist
among other groups that have not been studies such as general
practices. Recommendations from this study may not be generaliz-
able to areas within Europe that were not studied.
In conclusion, the EMA 2015 regulatory action targeting the
safety of hydroxyzine products was associated with consistent reduc-
tions in hydroxyzine initiation in two of the four countries, whilst hav-
ing limited impact on discontinuation and no switching of switching to
the classes of medication that we examined.
ACKNOWLEDGEMENTS
The authors acknowledge the Electronic Data Research and Innova-
tion Service (eDRIS) of ISD Scotland for providing the Scottish data
and for the general practices that contributed data to CPRD for public
health purposes. The study was funded by the European Medicines
Agency (Procurement procedure EMA/2014/50/RE). The EMA
approved the final study protocol and had no influence on the results
or decision to publish.
CONFLICT OF INTEREST
Elisabeth Smitsm Jetty A. Overbeek and Ron M. C. Herings are
employees of the PHARMO Institute for Drug Outcomes Research.
This independent research institute performs financially supported
studies for government and related healthcare authorities and several
pharmaceutical companies. TMM's university holds research grants
from Novartis, Ipsen, Teijin & Menarini. He is or has been the Principal
Investigator on trials paid for by Novartis, Ipsen, Teijin, RTI,
GlaxoSmithKline, SHIRE and Menarini. In the last 3 years he has been
paid consulting fees by Novartis and Merck. None of these studies
relate to hydroxyzine.
AUTHOR CONTRIBUTIONS
All authors were involved in the study design, approval of the study
protocol, interpretation of results and drafting of the manuscript.
ORCID
Daniel R. Morales https://orcid.org/0000-0002-0063-8069
Thomas M. MacDonald https://orcid.org/0000-0001-5189-6669
Jesper Hallas https://orcid.org/0000-0002-8097-8708
REFERENCES
1. European Medicines Agency. PRAC recommends new measures to mini-




2. Dusetzina SB, Higashi AS, Dorsey ER, et al. Impact of FDA drug risk
communications on health care utilization and health behaviours: a
systematic review. Med Care. 2012;50(6):466-478.
3. Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact
of medicines regulatory actions—systematic review and methodologi-
cal considerations. Br J Clin Pharmacol. 2018;84(3):419-433.
4. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile:
clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):
827-836.
5. Alvarez-Madrazo S, McTaggart S, Nangle C, Nicholson E, Bennie M.
Data resource profile: the Scottish National Prescribing Information
System (PIS). Int J Epidemiol. 2016;45(3):714-715f.
6. Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration
system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):
541-549.
7. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L,
S0rensen HT. The Danish National Patient Registry: a review of con-
tent, data quality, and research potential. Clin Epidemiol. 2015;7:
449-490.
8. Pottegard A, Schmidt SA, Wallach-Kildemoes H, S0rensen HT,
Hallas J, Schmidt M. Data resource profile: the Danish National Pre-
scription Registry. Int J Epidemiol. 2017;46(3):798-798f.
9. Penning-van Beest FJ1, Termorshuizen F, Goettsch WG, Klungel OH,
Kastelein JJ, Herings RM. Adherence to evidence-based statin guide-
lines reduces the risk of hospitalizations for acute myocardial infarc-
tion by 40%: a cohort study. Eur Heart J. 2007;28(2):154-159.
10. EU PAS Register. Impact of EU label changes for hydroxyzine prod-
ucts: post-referral prescribing trends. http://www.encepp.eu/
encepp/viewResource.htm?id=31082.
11. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented
regression analysis of interrupted time series studies in medication
use research. J Clin Pharm Ther. 2002;27(4):299-309.




MORALES ET AL. 9
13. Bahri P. Public pharmacovigilance communication: a process calling
for evidence-based, objective-driven strategies. Drug Saf. 2010;33
(12):1065-1079.
14. Weatherburn CJ, Guthrie B, Dreischulte T, Morales DR. Impact of
medicines regulatory risk communications in the United Kingdom on
prescribing and clinical outcomes: systematic review, time series anal-
ysis and meta-analysis. Br J Clin Pharmacol. 2020;86(4):698-710.
https://doi.org/10.1111/bcp.14104.
15. Guthrie B, Clark SA, Reynish EL, McCowan C, Morales DR. Differen-
tial impact of two risk communications on antipsychotic prescribing
to patients with dementia in Scotland: segmented regression time
series analysis 2001-2011. PLoS One. 2013;8(7):e68976.
16. Stocks SJ, Kontopantelis E, Webb RT, Avery AJ, Burns A,
Ashcroft DM. Antipsychotic prescribing to patients diagnosed with
dementia without a diagnosis of psychosis in the context of National
Guidance and drug safety warnings: longitudinal study in UK general
practice. Drug Saf. 2017;40(8):679-692.
17. Medicines Evaluation Board. Lower dosage for drugs containing
hydroxyzine. 2015. Available at: https://www.apothekersnieuws.nl/
lagere-dosering-voor-geneesmiddelen-met-hydroxyzine. Accessed
22/10/2020.
18. Alliance. New restrictions for hydroxyzine-containing medicines to








20. Morales DR, Morant SV, MacDonald TM, et al. Impact of EMA regula-
tory label changes on systemic diclofenac initiation, discontinuation,
and switching to other pain medicines in Scotland, England, Denmark,
and The Netherlands. Pharmacoepidemiol Drug Saf. 2020;29:296-305.
https://doi.org/10.1002/pds.4955.
21. Hedenmalm K, Blake K, Donegan K, et al. A European multicentre
drug utilisation study of the impact of regulatory measures on pre-
scribing of codeine for pain in children. Pharmacoepidemiol Drug Saf.
2019;28(8):1086-1096.
22. Sultana J, Fontana A, Giorgianni F, et al. Measuring the effectiveness
of safety warnings on the risk of stroke in older antipsychotic users: a
Nationwide cohort study in two large electronic medical records
databases in the United Kingdom and Italy. Drug Saf. 2019;42(12):
1471-1485.
23. Sultana J, Fontana A, Giorgianni F, et al. The effect of safety warnings
on antipsychotic drug prescribing in elderly persons with dementia in
the United Kingdom and Italy: a population-based study. CNS Drugs.
2016;30(11):1097-1109.
24. Berencsi K, Sami A, Ali MS, et al. Impact of risk minimisation measures
on the use of strontium ranelate in Europe: a multi-national cohort
study in 5 EU countries by the EU-ADR Alliance. Osteoporosis Int.
2020;31(4):721-755. https://doi.org/10.1007/s00198-019-05181-6.
25. Morales DR, Morant SV, MacDonald TM, et al. Impact of EU regula-
tory label changes for diclofenac in people with cardiovascular dis-
ease in four countries: interrupted time series regression analysis. Br J
Clin Pharmacol. 2020. https://doi.org/10.1111/bcp.14478. Epub
ahead of print. PMID: 32668021.
26. Hedenmalm K, Kurz X, Morales D. Effect of withdrawal of
fusafungine from the market on prescribing of antibiotics and other
alternative treatments in Germany: a pharmacovigilance impact study.
Eur J Clin Pharmacol. 2019;75(7):979-984.
27. Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiaze-
pines and risk of all cause mortality in adults: cohort study. BMJ.
2017;358:j2941.
28. Orriols L, Luxcey A, Contrand B, et al. Road traffic crash risk associ-
ated with prescription of hydroxyzine and other sedating
H1-antihistamines: a responsibility and case-crossover study. Accid
Anal Prev. 2017;106:115-121.
29. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calcu-
lation for designing interrupted time series analyses of health policy
interventions. J Clin Epidemiol. 2011;64(11):1252-1261.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Morales DR, Macfarlane T,
MacDonald TM, et al. Impact of EMA regulatory label changes
on hydroxyzine initiation, discontinuation and switching to
other medicines in Denmark, Scotland, England and the
Netherlands: An interrupted time series regression analysis.
Pharmacoepidemiol Drug Saf. 2021;1–10. https://doi.org/10.
1002/pds.5191
10 MORALES ET AL.
